New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2014
11:54 EDTICPTIntercept rises 14% to $343.49 as trial link circulated
Shares of Intercept Pharmaceuticals (ICPT) are significantly higher in late morning trading, with the move up potentially related to the circulation of a link to data on a clinical trial being run by Intercept for its study to test Obeticholic Acid's effectiveness when used in patients with moderately severe alcoholic hepatitis. The trial was initially posted to the government's ClinicalTrials.gov website in January, though it is unclear if new data has been made available via the site or otherwise. Reference Link
News For ICPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
06:26 EDTICPTIntercept price target lowered to $475 from $693 at Citigroup
Citigroup lowered its price target for Intercept shares to $475 on expectations investor concerns around the company's liver fibrosis drug, OCA, will persist. Citi, however, says it remains a buyer of the stock. It believes the level of concern around OCA’s cholesterol effect is overdone. The firm keeps a Buy rating on shares of Intercept.
December 18, 2014
06:33 EDTICPTIntercept coverage resumed with a Buy at Sterne Agee
Subscribe for More Information
December 15, 2014
08:58 EDTICPTIntercept reinstated with a Buy at BofA/Merrill
Subscribe for More Information
December 11, 2014
08:57 EDTICPTLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
December 5, 2014
06:06 EDTICPTIntercept announces publication of meta-analysis from Global PBC Study Group
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use